LiveBoost: A GB-based prediction system for liver fibrosis in chronic hepatitis B patients in China - A multi-center retrospective study
Guoxiang Xie,
Huanming Xiao,
Quan Liu,
Tianlu Chen,
Fengyan Chen,
Kejun Zhou,
Xiaoning Wang,
Ping Liu,
Zhifeng Jia,
Lei Chen,
Xin Deng,
Fankun Meng,
Zhenhua Zhang,
Xiaoling Chi,
Wei Jia
Affiliations
Guoxiang Xie
Human Metabolomics Institute Inc., Shenzhen, Guangdong, China; Corresponding author.
Huanming Xiao
Hepatology Department, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China
Quan Liu
Human Metabolomics Institute Inc., Shenzhen, Guangdong, China
Tianlu Chen
Center for Translational Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Fengyan Chen
Human Metabolomics Institute Inc., Shenzhen, Guangdong, China
Kejun Zhou
Human Metabolomics Institute Inc., Shenzhen, Guangdong, China
Xiaoning Wang
Institute of Interdisciplinary Integrative Medicine Research, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital, Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Ping Liu
Institute of Interdisciplinary Integrative Medicine Research, Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital, Department of Pharmacology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Zhifeng Jia
Department of Computer Science and Engineering, Hong Kong University of Science and Technology, Hong Kong, China
Lei Chen
Department of Computer Science and Engineering, Hong Kong University of Science and Technology, Hong Kong, China
Xin Deng
Hepatology Department, The Third People's Hospital of Shenzhen, Shenzhen, China
Fankun Meng
Ultrasound and Functional Diagnosis Center, Beijing Youan Hospital affiliated to Capital Medical University, Beijing, China
Zhenhua Zhang
Department of Infectious Diseases and Institute of Clinical Virology, The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Xiaoling Chi
Hepatology Department, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; Corresponding author.
Wei Jia
Human Metabolomics Institute Inc., Shenzhen, Guangdong, China; School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China; Corresponding author. Human Metabolomics Institute, Shenzhen, Guangdong, China.
Background: The aim of this study was to evaluate the accuracy of LiveBoost™, a gradient boosting (GB)-based prediction system based on standard biochemical values (AST, ALT, platelet count) and age, in Chinese patients with chronic hepatitis B (CHB) and compare its performance with FIB-4 (fibrosis-4 score) and APRI (the aspartate transaminase to platelet ratio index). Methods: This retrospective trial enrolled 454 participants, including 279 CHB patients who underwent liver biopsy and 175 normal controls from 3 centers in China. All participants underwent laboratory blood testing. LiveBoost was constructed using GB and FIB-4 and APRI were calculated from laboratory data. Results: LiveBoost outperformed APRI and FIB-4 in predicting hepatic fibrosis and cirrhosis. The GB model had an AUROC of 0.977 for CHB diagnosis, 0.804 for early and advanced fibrosis, and 0.836 for non-cirrhosis and cirrhosis, compared to AUROC of 0.554, 0.673 and 0.720 for FIB-4, AUROC of 0.977, 0.652 and 0.654 for APRI. Conclusions: LiveBoost is a more reliable and cost-effective method than APRI and FIB-4 for assessing liver fibrosis in Chinese patients with CHB.
